Harnessing the power of advanced Biomarkers and Omics

  • Omics technologies are medical revolution. They are key to unraveling the complex origins of Fontan-related comorbidities.
  • Better biomarkers: we are also exploring the full potential of existing biomarkers, whether they are published in literature on Fontan circulation and general cardiology.
  • Aim: to develop an accurate prognosis: By strategically employing biomarkers, we aim to improve diagnostics, foresee long-term complications, and predict major adverse events with accuracy.